Table 1.
Current FDA-approved GLP-1R agonists and dosing
| GLP-1R Agonist | Route | Dosing |
|---|---|---|
| Short-acting | ||
| Exenatide | SC | Twice daily |
| Lixisenatide | SC | Once daily |
| Long-acting | ||
| Exenatide extended release | SC | Once weekly |
| Liraglutide* | SC | Once daily |
| Dulaglutide | SC | Once weekly |
| Semaglutide* | SC or PO | Once weekly SC or once daily PO |
*
All GLP-1R agonists are currently approved for use in T2D with the exception of liraglutide and semaglutide, which are also approved for chronic weight management and weight loss in obesity
GLP-1R, glucagon-like peptide-1 receptor; T2D, type 2 diabetes mellitus; SC, subcutaneous; PO, oral